Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | LOXO-435 |
Synonyms | |
Therapy Description |
LOXO-435 is an isoform-selective inhibitor of FGFR3 with potential antitumor activity (Cancer Res (2023) 83 (8_Supplement): CT119). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
LOXO-435 | LOXO 435|LOXO435|LY3866288|LY 3866288|LY-3866288 | FGFR3 Inhibitor 19 | LOXO-435 is an isoform-selective inhibitor of FGFR3 with potential antitumor activity (Cancer Res (2023) 83 (8_Supplement): CT119). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05614739 | Phase I | LOXO-435 + Pembrolizumab LOXO-435 | A Study of LOXO-435 in Participants With Cancer With a Change in a Gene Called FGFR3 | Recruiting | USA | NOR | NLD | ITA | ISR | GBR | FRA | ESP | DEU | CAN | AUS | 3 |